Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-26T10:06:28.887Z Has data issue: false hasContentIssue false

Moving from Q fever to C. burnetii infection

Published online by Cambridge University Press:  26 November 2015

C. ELDIN
Affiliation:
Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Faculté de Médecine, Aix-Marseille Université, Marseille, France
D. RAOULT*
Affiliation:
Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Faculté de Médecine, Aix-Marseille Université, Marseille, France
*
*Author for correspondence: D. Raoult (Email: [email protected])
Rights & Permissions [Opens in a new window]

Abstract

Type
Correspondence
Copyright
Copyright © Cambridge University Press 2015 

To the Editor

This paper by Van Loenhout et al. [Reference Van Loenhout1] gives us the opportunity to discuss the accuracy of the EU case definition for notification of Q fever, and more generally the current nomenclature of this infection.

In the EU definition, cases of ‘acute Q fever’ are defined by the combination of clinical symptoms (fever, pneumonia, hepatitis) and laboratory criteria. As stated by the authors, the major limitation of this classification is that it probably significantly underestimated the number of cases of Coxiella burnetii primary infection during The Netherlands epidemic. Interestingly, the use of this definition can be used to compare symptomatic (notified as ‘acute Q fever’) and asymptomatic or poorly symptomatic (non-notified) C. burnetii primary infections. The main significant differences between these two groups are age and sex, with symptomatic patients being significantly older and more often men than asymptomatic or poorly symptomatic patients. This result confirms what has already been described in previous studies: age and sex are the two major determinants of clinical manifestations of C. burnetii primary infection, with older men being more frequently symptomatic than young women, pregnant women and children [Reference Tissot-Dupont2Reference Leone4]. Moreover, the results of Van Loenhout et al. confirm that there is no correlation between clinical manifestations of C. burnetii primary infection and the long-term consequences of the infection, with no significant difference in long-term health status between notified and non-notified patients [Reference Million and Raoult5].

These elements bring new arguments for an updated nosography of C. burnetii infection. We consider that the natural history of C. burnetii infection is quite close to what is observed in Mycobacterium tuberculosis infection (TB), so that the old simplistic classification of ‘acute’ and ‘chronic Q fever’ is no longer accurate. In TB, the primary infection can be symptomatic or not. If left untreated, and in the presence of host factors like immunosuppression or age, long-term complications of the infection can occur and affect different organs (Pott's disease, meningitis, miliary, lymphadenitis). Localization of the focus of infection is necessary to determine treatment duration and prognosis. In the case of C. burnetii, the primary infection can be symptomatic (currently described as ‘acute Q fever’) or not, depending on two major determinants: the strain involved [Reference D'Amato6] and the patient's susceptibilities (age, sex, pregnancy, immunosuppression) [Reference Raoult7]. Then, long-term complications can be classified into two main entities: persistent focalized infections and fatigue syndrome (without an identified focus of infection). These complications are not linked to the severity of the primary infection but mainly to host factors. There is no ‘chronic Q fever’ with multiplying C. burnetii without a focus of infection and different focalized persistent infections have different risk factors, prognoses and treatments. C. burnetii endocarditis occurs in subjects with pre-existing valvulopathy, and is associated with high IgG anticardiolipin antibody titres during primary infection [Reference Million8]. Its prognosis has improved thanks to prophylaxis, early diagnosis and treatment [Reference Million9]. Vascular infections occur in patients with pre-existing aneurysm or vascular grafts, requires surgical treatment and still has a very poor prognosis [Reference Botelho-Nevers10]. Conversely, no death has been reported to date in patients with C. burnetii osteoarticular infections [Reference Million11, Reference Angelakis12]. C.burnetii infection during pregnancy is frequently asymptomatic but can lead to severe obstetrical complications like fetal death and malformations [Reference Million13]. Finally, we recently demonstrated that C. burnetii persistent lymphadenitis can lead to lymphoma [Reference Melenotte14].

Regarding fatigue syndrome, a disease without evidence of C. burnetii multiplication and not treatable with antibiotics, this paper demonstrates that it is equally frequent after C. burnetii symptomatic and asymptomatic primary infections. Recently, another study from The Netherlands on ‘Q fever fatigue syndrome’ used the definition of the National Dutch consensus guidelines, which is cited as follows: ‘a sudden onset of fatigue related to a symptomatic acute Q fever infection’ [Reference Keijmel15]. Given the data from Van Loenhout et al. [Reference Van Loenhout1], this definition is obviously misleading. Further studies using a definition allowing detection of fatigue syndrome after C. burnetii asymptomatic primary infections are necessary to reach a conclusion on the actual occurrence and risk factors of this syndrome.

In conclusion, the work of Van Loenhout et al. stresses the need for moving from the old unspecific ‘Q fever’ nomenclature to more precise definitions of the different forms of C. burnetii infection in order to establish efficient public health strategies. In epidemic situations like the one experienced in The Netherlands, detection and follow-up of asymptomatic C. burnetii primary infections should be a priority, especially in high-risk patients (valvulopathy, vascular aneurysms or prosthesis, osteoarticular prosthesis, pregnant women) to detect and prevent the development of both focalized persistent infections and fatigue syndrome.

Declaration of Interest

None.

References

1. Van Loenhout, JA, et al. Severely impaired health status of non-notified Q fever patients leads to an underestimation of the true burden of disease. Epidemiology and Infection 2015; 143: 25802587.Google Scholar
2. Tissot-Dupont, H, et al. Role of sex, age, previous valve lesion, and pregnancy in the clinical expression and outcome of Q fever after a large outbreak. Clinical Infectious Diseases 2007; 44: 232237.Google Scholar
3. Tissot, Dupont H, et al. Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. American Journal of Medicine 1992; 93: 427434.Google Scholar
4. Leone, M, et al. Effect of sex on Coxiella burnetii infection: protective role of 17beta-estradiol. Journal of Infectious Diseases 2004; 189: 339345.CrossRefGoogle ScholarPubMed
5. Million, M, Raoult, D. Recent advances in the study of Q fever epidemiology, diagnosis and management. Journal of Infection 2015; 71 (Suppl. 1): S29.Google Scholar
6. D'Amato, F, et al. Loss of TSS1 in hypervirulent Coxiella burnetii 175, the causative agent of Q fever in French Guiana. Comparative Immunology Microbiology and Infectious Diseases. Published online: 7 May 2015. doi:10.1016/j.cimid.2015.04.003.CrossRefGoogle ScholarPubMed
7. Raoult, D, et al. Q fever 1985–1998. Clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore) 2000; 79: 109123.Google Scholar
8. Million, M, et al. Immunoglobulin G anticardiolipin antibodies and progression to Q fever endocarditis. Clinical Infectious Diseases 2013; 57: 5764.CrossRefGoogle ScholarPubMed
9. Million, M, et al. Long-term outcome of Q fever endocarditis: a 26-year personal survey. Lancet Infectious Diseases 2010; 10: 527535.CrossRefGoogle ScholarPubMed
10. Botelho-Nevers, E, et al. Coxiella burnetii infection of aortic aneurysms or vascular grafts: report of 30 new cases and evaluation of outcome. European Journal of Clinical Microbiology and Infectious Diseases 2007; 26: 635640.CrossRefGoogle ScholarPubMed
11. Million, M, et al. Culture-negative prosthetic joint arthritis related to Coxiella burnetii . American Journal of Medicine 2014; 127: 786.e7–786.e10.Google Scholar
12. Angelakis, E, et al. Emergence of Q fever arthritis in France. Journal of Clinical Microbiology 2014; 52: 10641067.CrossRefGoogle ScholarPubMed
13. Million, M, et al. Reevaluation of the risk of fetal death and malformation after Q fever. Clinical Infectious Diseases 2014; 59: 256260.CrossRefGoogle ScholarPubMed
14. Melenotte, C, et al. B-cell non-Hodgkin lymphoma linked to Coxiella burnetii. Blood (in press).Google Scholar
15. Keijmel, SP, et al. A comparison of patients with Q fever fatigue syndrome and patients with chronic fatigue syndrome with a focus on inflammatory markers and possible fatigue perpetuating cognitions and behaviour. Journal of Psychosomatic Research 2015; 79: 295302.Google Scholar